MELISSA LACAYO: Open Payments
NPI 1639799265 · BELL, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$964 in 43 payments from 18 companies in 2025. Trend: 2023 $965 · 2024 $1,423 · 2025 $964
Food & beverage: $964
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $142 |
| Lilly USA, LLC | 5 | $122 |
| GlaxoSmithKline, LLC. | 4 | $92 |
| Novo Nordisk Inc | 4 | $87 |
| Dexcom, Inc. | 3 | $85 |
| Sumitomo Pharma America, Inc. | 3 | $83 |
| AstraZeneca Pharmaceuticals LP | 3 | $55 |
| Lundbeck LLC | 3 | $55 |
| SANOFI-AVENTIS U.S. LLC | 1 | $40 |
| Amgen Inc. | 2 | $37 |
Products named: JARDIANCE, MOUNJARO, Dexcom G6 Transmitter, GEMTESA, REXULTI, TRELEGY ELLIPTA, TZIELD, KRYSTEXXA.
Industry payments across CA — which companies pay providers there.
